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Abstract
Objective. To describe the use of and response to biologic therapies commenced in adults with JIA.
Methods. Patients with arthritis onset <16 years were identified from the British Society for Rheumatology
Biologics Register for rheumatoid arthritis (BSRBR-RA) and stratified into ILAR JIA subtypes. Patterns of
biologic use and treatment persistence were explored, with disability levels (HAQ) and remission rates
[28-Joint Disease Activity Score (DAS28)] evaluated at 6 and 12 months.
Results. Arthritis with an onset of <16 years was confirmed in 225 patients and the ILAR subtype was
determined in 154 (68%). Only 58 (26%) patients had a diagnosis of JIA recorded in the BSRBR-RA. The
median age at biologic commencement was 31 years [interquartile range (IQR) 2339] and 76% were
female. The biologic therapies were etanercept (49%), infliximab (28%), adalimumab (22%) and anakinra
(1%). Fifty per cent of patients received more than one biologic during follow-up (2 agents, n = 64; 53
agents, n = 49). Treatment persistence at 1 year was 78% (95% CI 71%, 82%), falling to 42% (95% CI
34%, 49%) at 5 years. Both the HAQ and DAS28 improved significantly at 6 months, with 21% and 28%
of patients in remission (DAS28<2.6) at 6 and 12 months, respectively.
Conclusion. This study describes patterns and identifies outcomes of biologic use in a national cohort of
adults with JIA. With no national guidance currently available in this area, the choice of first biologic was
inconsistent, although treatment outcomes were good. These data confirm that biologic therapies are an
important treatment option in adults with active JIA in adulthood.
Key words: anti-TNF therapy, disease activity, treatment outcome, juvenile idiopathic arthritis.
Introduction
JIA is one of the most common chronic illnesses of child-
hood, with an incidence of 10/100 000 children-years in
the UK [1]. JIA is not a disease confined to childhood,
with more than one-third of patients continuing to have
episodes of active inflammation during their adult years
[24]. The evidence base for the optimal management of
adults with JIA is lacking, in part due to the complexity of
obtaining very long-term follow-up data in children with
chronic illness.
The management of JIA has traditionally been modelled
on the management of RA, with MTX and now anti-TNF
medications forming the mainstay of therapy [59].
However, JIA is an umbrella term for a group of related
childhood-onset arthritides, many of which are quite dif-
ferent from RA. Adults with JIA are a heterogeneous group
with different clinical characteristics than adults with other
inflammatory arthritides [2, 10]. Optimal management and
outcomes of JIA may therefore differ from RA. As our
understanding of the variation between the ILAR subtypes
of JIA increases [11, 12], we can begin to hypothesize that
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the response to anti-TNF therapies may also differ
according to subtype.
The use and benefit of anti-TNF therapies in adults with
persistent JIA is poorly described. Therefore, using data
from adults with JIA registered within the British Society
for Rheumatology Biologics Register Rheumatoid Arthritis
(BSRBR-RA), this study aims to describe (i) the distribu-
tion of ILAR subtypes among UK patients with JIA starting
treatment with biologic therapies in adulthood, (ii) the pat-
tern of biologic use in this population and (iii) the reasons
for discontinuation of the primary biologic therapy and
early treatment response data.
Methods
Study population
The BSRBR-RA is a prospective, national, longitudinal,
observational study established in October 2001 [13].
The main aim of the study is to examine the long-term
safety of biologic agents in patients with RA in the UK
[14]. The BSRBR-RA recruited patients with RA starting
etanercept between 2001 and 2005, adalimumab be-
tween 2003 and 2008 and infliximab between 2001 and
2007, with a target RA recruitment of 4000 patients start-
ing each drug. Patients with other rheumatic diseases,
including JIA, were eligible to be recruited at any time,
with the exception of AS and PsA, for which recruitment
stopped in 2006.
Ethics approval was obtained for the BSRBR-RA in
December 2000 from the Multicentre Research Ethics
Committee (MREC) for the North-West of England and
all patients gave written informed consent to participate
in the study.
Data collection
At the start of biologic therapy, clinical teams complete a
baseline questionnaire that includes information on diag-
nosis, date of symptom onset, current disease activity
[using the RA 28-joint Disease Activity Score (DAS28), a
composite score including a 28 swollen joint count, 28
tender joint count, ESR and a patient global assessment]
[15] and details of past and current DMARD and biologic
use. Information on co-morbidities is collected at base-
line. The patient completes an HAQ standardized for UK
use [16]. Follow-up data are collected every 6 months for
3 years from the rheumatologist and patient, then annually
from the rheumatologist thereafter. Physician-derived
follow-up details include disease activity assessment
(DAS28), anti-rheumatic drug details, including dates
and reasons for cessation if appropriate, and adverse
events. Patients are requested to complete an HAQ
every 6 months for 3 years.
Subject selection and definition
All patients with a recorded onset of arthritis prior to their
16th year were identified from the register to ensure iden-
tification of all patients with JIA, including those labelled
with a diagnosis other than JIA by the treating rheuma-
tologist. In all cases the current treating rheumatologist
was contacted and asked to provide further information
to confirm a diagnosis of JIA and to establish an ILAR
classification.
Data analysis
This analysis was limited to those individuals with a con-
firmed diagnosis of JIA (idiopathic arthritis lasting >6
weeks with onset prior to the 16th birthday) [11, 12].
Physician-derived data were analysed to determine the
reasons for stopping the primary biologic. KaplanMeier
survival curves were used to describe treatment persist-
ence with the patient’s first anti-TNF therapy. Patients
were censored at date of death, first missed dose or last
follow-up if still on treatment, whichever came first.
Temporary stops of <90 days (commonly for surgery or
adverse events such as infection), followed by recom-
mencement of the same anti-TNF therapy, were counted
as continuous use of the drug.
Changes in disability were assessed at 6 and 12 months
using changes in the HAQ score from baseline [17]. A
minimal clinically important difference (MCID) was defined
as an improvement in the HAQ score of at least 0.22 units
[18]. Disease activity at 6 and 12 months following com-
mencement of the primary biologic therapy was deter-
mined using the DAS28 [15]. Response was categorized
using the European League Against Rheumatism (EULAR)
response criteria into good, moderate or non-response
based on changes in the DAS28 and final DAS28 achieved
[19] and remission was defined as a DAS28 <2.6 [19, 20].
Non-parametric descriptive statistics were used to com-
pare the response between groups and across time
points. STATA 10.1 software was used for all statistical
analyses (STATA Corporation, College Station, TX, USA).
Results
Patient characteristics
Through January 2010, 495 patients were identified as
having a possible onset of arthritis prior to their 16th birth-
day. The clinical teams returned 234 forms, with the diag-
nosis of JIA confirmed in 225 patients. The reporting
clinicians provided sufficient information to further classify
the ILAR subtype in 154/225 (68%) patients.
Just 26% of patients in this cohort were reported to
have JIA by the treating clinical team on the baseline
questionnaire (Table 1)—22% as the primary diagnosis
and 4% as a secondary diagnosis (primary label RA).
Most patients (78%) had another primary rheumatologic
diagnosis {RA, n = 129; AS, n = 23; PsA, n = 16; other,
n = 8, including 4 seronegative arthritides [confirmed
ILAR subtype: 1 psoriatic JIA (JPsA), 2 enthesitis-related
arthritides (ERA) and one with insufficient information to
differentiate between the two], 1 inflammatory arthritis
(ILAR subtype: JPsA) and 3 adult-onset Still’s disease
(ILAR subtype: extended oligoarticular JIA(EO) and 2
unknown}.
Baseline characteristics and biologic prescribing pat-
terns in the final study cohort are presented in Table 2.
The median age of the cohort at commencement of the
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primary biologic was 31 years [interquartile range (IQR)
2339], 76% female. The median disease duration since
diagnosis was 21 years (IQR 1230). The proportion of
female patients differed significantly with the ILAR sub-
type (P< 0.001), with a higher proportion of males in the
ERA and PsA subtypes. There was no significant differ-
ence in any other baseline characteristics across the ILAR
subtypes.
Many (56%) patients received their biologic in combin-
ation with MTX (alone or with another DMARD) and 35%
had discontinued all DMARDs at commencement of bio-
logic therapy. The median number of previous DMARDs
was 3 (IQR 25). The primary biologic therapy was etaner-
cept in 49%, infliximab in 28%, adalimumab in 22% and
anakinra in 1%. There was no significant difference in pri-
mary biologic therapy across the ILAR subtypes, although
infliximab was more commonly prescribed for patients
with oligoarticular JIA and ERA. Fifty per cent received
more than one anti-TNF over the study period, with 22%
receiving three or more anti-TNF therapies.
We were unable to establish the ILAR category for 71
subjects. Fifty-seven (80%) had a polyarticular disease
course, but missing information such as RF titres (missing
in 21/57) or the number of joints involved in the first 6
months (missing in 19/57) rendered the ILAR subtype in-
determinable. The majority of this subgroup had a higher
median age than patients with the ILAR subtype available
[36 years (IQR 2442) vs 29 years (IQR 2238), P = 0.04]
and longer median disease duration since diagnosis [25
years (IQR 1531) vs 19 years (IQR 1127), P = 0.0027].
Treatment persistence and reasons for treatment
discontinuation
Consultant-derived follow-up data (including anti-rheum-
atic drug details) were available in 222/225 patients (99%).
In total there were 590 person-years of observation
(median person-years per patient 2.4 years, range
0.067.2 years). Overall, 114/222 (51%) patients discon-
tinued the primary biologic therapy (Table 3), 45/114
(39%) for inefficacy and 38/114 (33%) for adverse
events. No serious adverse events (fatal or otherwise
life-threatening, resulting in unplanned or prolonged hos-
pitalization, physically disabling or resulting in a birth
defect) were reported as a reason for stopping biologic
therapy. Reasons cited for stopping medication in the
other category most commonly included pregnancy
(n = 7) and planned surgery (n = 5). No patients were re-
corded as stopping the drug for remission. The probability
of remaining on the primary biologic therapy was 78%
(95% CI 71%, 82%) at 1 year (Fig. 1). This dropped to
42% (95% CI 34%, 49%) at 5 years, with a median drug
survival of 3.3 years.
Effect of biologic therapy on disease activity (DAS28)
The DAS28 was available for 91% of patients at baseline,
with a median score of 6.3, with 84% >5.1 (Table 4), and
no significant variation with the ILAR subtype (P = 0.62).
The median DAS28 at 6 months was 3.8 (IQR 2.74.9),
with little change at 12 months [3.7 (IQR 2.55.2)].
Few patients (3/204, 1.5%) had a DAS28 compatible
with remission (DAS28< 2.6) at the start of treatment;
36/172 (21%) and 42/151 (28%) were in DAS28 remission
at 6 and 12 months, respectively (Table 4). Overall, 4%
patients had no swollen joints at baseline (based on a 28-
joint count), increasing to 26% at 6 months and 33% at 1
year. Two per cent of patients had no tender joints at
baseline, increasing to 18% at 6 months and 22% at 12
months. No patients had a patient global assessment of
0 cm at baseline, increasing to 13% at 6 months and 6%
at 1 year. There was no significant difference in remission
rates between ILAR subtypes of JIA at 6 or 12 months
(P = 0.71 and P = 0.055, respectively), although more pa-
tients with ERA and JPsA achieved remission at 12
months, with a trend towards significance.
Effect of biologic therapy on disability (HAQ)
HAQ scores were available for 88% of patients at base-
line, 61% at 6 months and 56% at 12 months (Table 5).
The median baseline HAQ decreased significantly by 6
months (P< 0.001) and was sustained at 12 months
(P< 0.001). No statistically significant difference was
seen in baseline HAQ (P = 0.08) or HAQ improvement
TABLE 1 Diagnostic label in the BSRBR-RA database




PJIA ERA JPsA UnJIA
Subtype
unknown Total
Number, % 11 (5) 38 (17) 19 (8) 36 (16) 24 (11) 26 (12) 0 71 (31) 225
Primary diagnostic label in
registry, n (%)
JIA 4 (36) 11 (29) 8 (42) 3 (8) 3 (12) 4 (15) 16 (23) 49 (22)
RA 7 (64) 26 (68) 11 (58) 33 (92) 4 (17) 6 (23) 42 (59) 129 (57)
PsA 0 0 0 0 0 13 (50) 3 (4) 16 (7)
AS 0 0 0 0 15 (62) 1 (4) 7 (10) 23 (10)
Other (not JIA) 0 1 (3) 0 0 2 (9) 2 (8) 3 (4) 8 (4)
JIA documented
anywhere on baseline form, %
4 (36) 15 (39) 10 (53) 5 (14) 3 (12.5) 5 (19) 16 (23) 58 (26)
SJIA: systemic onset JIA; POJIA: persistent oligoarticular JIA; EO: extended oligoarticular JIA; RF PJIA: RF-negative poly-
articular JIA; RF+ PJIA: RF-positive polyarticular JIA; PJIA: psoriatic JIA; UnJIA: unclassifiable JIA.
www.rheumatology.oxfordjournals.org 3
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across the ILAR subtypes (P = 0.36 at 6 months and
P = 0.39 at 12 months). A similar proportion of patients
achieved a minimal clinically important difference
(MCID> 0.22) in the HAQ at 6 and 12 months across the
ILAR subtypes (P = 0.33 at 6 months and P = 0.38 at 12
months), although the numbers of patients were very
small.
Discussion
This study is the first to describe prescribing patterns of
biologic therapies in UK adults with JIA, demonstrating
their efficacy both in terms of reduced disease activity
and reduced disability. It reports a number of interesting
findings, including a relatively high frequency of switching
between biologic therapies and relatively high remission
rates for adults with JIA compared with RA patients in the
same cohort. It also demonstrates that the adults included
in this study had severe disease, indicated by the median
baseline HAQ score of 2.0 and higher levels of depression
than are estimated for the general adult population (19%
vs an estimated 11%) [21].
Patients with RF+ JIA, ERA and JPsA are over-repre-
sented in this cohort in comparison to paediatric cohorts
in general [22]. This is likely to be explained by patterns of
remission in JIA; the probability of complete remission in
JIA within 10 years is highest in oligoarticular and lowest in
RF+ polyarticular disease [23, 24]. The ILAR subtype dis-
tribution of this cohort reflects these remission patterns,
confirming the relatively poor prognoses of the RF+, ERA
and JPsA subtypes. Although the mean age of this cohort
is lower than the mean age of RA patients in the BSRBR-
RA, the median disease duration prior to the first biologic
is 5 years longer [25]. Although this may relate to the avail-
ability and licensing of anti-TNF therapies compared with
the onset of the disease, it is also possible that clinicians
found it more difficult to obtain funding permissions for
biologic therapies for adults with JIA. At the time of this
study, no specific UK treatment guidelines for anti-TNF
therapies in adult patients with JIA had been published.
Current published guidelines for polyarticular JIA in the UK
extend from 4 to 17 years [26].
Just 26% of patients with a confirmed diagnosis of JIA
were listed as having JIA on their baseline questionnaire,
with the majority listed as having RA. Possible explan-
ations include incomplete information at transfer to adult
services and a potential perception among reporting clin-
icians that JIA patients are less likely to receive funding for
biologic therapies, as there is no guidance/consensus for
their use, with the consequence that an adult rheumatic
disease diagnosis is listed in the medical record. Patients
with RF+, ERA and JPsA are less likely to be labelled with
JIA; implying difficulty with diagnostic labelling is maximal
within these subtypes.
Many patients (42%) with 5 years of follow-up data
available remain on the primary biologic therapy, similar
to rates observed in patients with RA from this same
population [27]. Although the numbers are small, this sug-
gests that biologic therapies can be efficacious in the
short to medium term. Many (50%) patients in this
cohort were prescribed more than one biologic therapy.
Although 33% discontinued the primary biologic for ad-
verse events, 39% switched for inefficacy, indicating on-
going active disease on the primary biologic.
There was no clear pattern to the primary biologic ther-
apy, with 49% receiving etanercept, 28% infliximab and
22% adalimumab. The BSRBR-RA cannot be used to
comment on prescribing patterns over time due to the
study design, which was a cohort study rather than an
open register.
However, an anecdotal risk of uveitis flare has been
described with etanercept, so it is possible that infliximab
or adalimumab were chosen in patients with uveitis [28].
This is supported by the increased frequency of infliximab
as the primary biologic in the oligoarticular subtype. The
presence of uveitis could not be ascertained in this cohort
since uveitis is not recorded in the BSRBR-RA dataset.
TABLE 3 Physician-reported reasons to stop primary biologic therapy
Stop reason Etanercept Infliximab Adalimumab Anakinra Total, n (%)
Still on drug 66 19 22 1 108 (49)
Inefficiency 17 18 10 0 45 (20)
Adverse event 13 13 12 0 38 (17)
Other 13 14 4 0 31 (14)
Total 109 64 48 1 222
FIG. 1 KaplanMeier curve illustrating survival time on the
primary biologic.
www.rheumatology.oxfordjournals.org 5
Biologic use in adults with JIA





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Flora McErlane et al.









Anakinra was prescribed to one subject with RF+ JIA. The
use of anakinra in polyarticular JIA has been described,
although there is no good evidence for its efficacy [29].
There is good evidence for the efficacy of anakinra in sys-
temic-onset JIA, but anakinra was not used for any
patients with this subtype [30].
Remission rates at 6 and 12 months were determined
through application of the RA DAS28 and EULAR
response criteria [15, 19]. Very little is known about the
validity of outcome measures in adults with JIA. No com-
posite disease activity score has been validated for use in
adults with JIA, including the recently introduced Juvenile
Arthritis Disease Activity Score (JADAS) [31]. The DAS28
is likely to reflect disease activity most accurately in poly-
articular patterns of disease, but has been criticized in
adult psoriatic arthritis [32]. For similar reasons, the
DAS28 may not be an effective measure of overall disease
activity in a number of the ILAR subtypes. However, since
composite disease activity scores should predict out-
comes more accurately than their individual components,
a decision was made to apply the DAS28 to this cohort of
adults with JIA, accepting the potential limitations of this
tool. This cohort has very long-standing disease (median
disease duration 19 years), significantly longer than that
observed in RA cohorts [33]. Despite this, the response to
biologic therapy is very good, with remission rates (21%)
better than those observed in RA patients (9%) and similar
to those in patients with psoriatic arthritis (27.5%) within
the same population [25, 34]. The heterogeneity of JIA
makes it difficult to draw meaningful comparisons be-
tween patients with JIA and more homogeneous groups
of patients with adult inflammatory diseases.
The HAQ is a robust measure of disability used in the
assessment of functional ability in previous studies of
adults with JIA [2, 10, 24, 3539]. The median HAQ at
baseline, 6 and 12 months in this population does not
vary with the ILAR subtype of JIA, suggesting a similar
threshold of disability corresponding to commencement
of biologic therapy within the different ILAR subtypes.
The median HAQ decreases significantly from baseline
to 6 months and baseline to 12 months and many patients
exceed the MCID in the HAQ. Since there is no validated
MCID for adults with JIA, the definition of MCID derived
from populations of adults with RA has been applied to
this cohort. Disability levels in childhood JIA have been
shown to drop dramatically following commencement of
etanercept [5, 6]. Longer-term follow-up of larger cohorts
of adults with JIA on biologic therapies would help estab-
lish the clinical relevance of the changes noted.
This study has a number of limitations. Details regarding
confirmation and subtype of JIA were collected retro-
spectively. We could only confirm or refute the diagnosis
of JIA in 47% of our cohort due to physician non-re-
sponse. The reasons for this were not known but resulted
in the exclusion of up to 261 further cases, thus potentially
introducing a degree of selection bias into our data.
Compared with the large sample size within the
BSRBR-RA cohort, the sample size of this cohort is
small. Although this may reflect a low absolute number
of adults with JIA starting biologics in the UK, registration
of adults with JIA commencing biologic treatment with the
BSRBR-RA is not mandatory. Therefore this study may
not have captured all adults with JIA in the UK commen-
cing biologic therapies in adult life. HAQ scores were not
available at follow-up in >40% of patients, introducing the
possibility of selection bias. This level is slightly higher
than that reported in the overall BSRBR-RA cohort, re-
cently estimated at 30% (reference my moderate disease
activity paper from 2009 - PMID:19706737), and therefore
further bias may have been introduced.
We are aware that many adults with JIA will have com-
menced biologic therapies in childhood, rendering this
cohort unrepresentative of all adults with JIA currently
on biologics within the UK. However, in the absence of
robust long-term follow-up of paediatric JIA cohorts, this
is the largest cohort of adults with JIA commencing bio-
logic therapies reported to date and these data are im-
portant, emphasizing the need for long-term surveillance
in this heterogeneous condition.
The Juvenile arthritis MTX/Biologics long-term
Observation (JuMBO) study recently published data on
346 adults with JIA commenced on etanercept during
childhood [40]. Almost half (45%) of the cohort remained
on etanercept alone in adult life (median follow-up period
6.5 years, IQR 4.28.4 years), with a median of 3.5 bio-
logic and non-biologic DMARDS other than etanercept
(range 113) over the course of the disease [40]. In com-
parison, 42% of our cohort of patients commencing bio-
logics in adulthood remained on the primary biologic at 5
years, with 50% receiving more than one and 22% receiv-
ing multiple anti-TNF therapies. This study provides fur-
ther evidence of the importance of biologic therapies in
adults with JIA and is the first to document the efficacy of
biologic therapies commenced in JIA patients during
adulthood.
All 225 patients fulfilled diagnostic criteria for JIA,
although the ILAR subtype could not be determined in
71/225 patients (32%). There are significant differences
in baseline demographics between these 71 patients
and the final study cohort. Many of those excluded fulfilled
criteria for more than one ILAR subtype, but missing
information meant they could not be classified as undif-
ferentiated JIA. The ILAR classification system can be dif-
ficult to apply to adults with JIA and the missing
information on many patients in this study highlights the
difficulties associated with retrospective data collection.
Important information such as the number of joints
involved in the first 6 months can be lost over time.
The inability to classify 32% of the patients in this cohort
may reflect incomplete clinical information at transfer from
paediatric to adult services. This phenomenon is well
documented [41], highlighting the need for long-term
follow-up of large prospective cohorts of children with
JIA such as the Childhood Arthritis Prospective Study
(CAPS) [22]. It is extremely important that safety and effi-
cacy studies for biological agents in JIA extend from child-
hood into the adult years, with existing paediatric
registries supported to facilitate long-term follow-up.
www.rheumatology.oxfordjournals.org 7
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In summary, this study increases the body of evidence
for persistence of severe active JIA into adult life, adds
further information about the demographics of adults with
active JIA and demonstrates that biologic therapies are
integral to the management of this group. It highlights
how little is known about the management of adult JIA
and the factors influencing the choice of therapy.
Anecdotally, the choice of biologic therapy is influenced
by patient choice, adherence history, clinical features that
may be particular to JIA (such as flare of uveitis or sys-
temic features), access to treatment centres and funding.
There is no consensus about optimal care or biologic use
in adult JIA, although the results of this study suggest
response after 5 years is good, with similar drug survival
to that seen in RA and perhaps higher rates of remission.
Rheumatology key messages
. Biologic therapies are integral to the management
of adults with severe JIA, reducing disease activity
and disability.
. There is no consensus about the optimal manage-
ment of JIA in adulthood and the factors influencing
the choice of therapy.
. Prescribing patterns of biologic therapies in adults
with JIA are variable.
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